Skip to main content
. Author manuscript; available in PMC: 2022 May 5.
Published in final edited form as: Hypertension. 2021 Mar 29;77(5):1528–1538. doi: 10.1161/HYPERTENSIONAHA.120.16402

Figure 1.

Figure 1.

The meta-analytic HR estimates and their 95% CIs comparing the relative risk of acute myocardial infarction, stroke, and hospitalization for heart failure between third-generation beta-blockers (carvedilol and nebivolol) versus atenolol (PS matching, on-treatment)

Abbreviations: HR, hazard ratio; CI, confidence interval; 3rd BB, third-generation beta-blocker; PS, propensity score; CCAE, Truven MarketScan Commercial Claims and Encounters; Optum, Optum ClinFormatics; Panther, Optum de-identified Electronic Health Record Dataset